Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.52 |
| ▸ | JAK1 | P23458 | 17/20 | 0.52 |
| ▸ | JAK2 | O60674 | 12/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23668184 | 0.88 | JAK1 (0.54) | LRRK2JAK1JAK2 | |
| SCHEMBL21808611 | 0.83 | LRRK2 (0.54) | LRRK2JAK1JAK2JAK3 | |
| SCHEMBL21870754 | 0.81 | LRRK2 (0.61) | LRRK2JAK1JAK2 | |
| SCHEMBL30810130 | 0.81 | LRRK2 (0.61) | LRRK2JAK1JAK2 | |
| SCHEMBL21870747 | 0.78 | LRRK2 (0.60) | LRRK2JAK1JAK2 | |
| SCHEMBL31470481 | 0.78 | LRRK2 (0.51) | LRRK2JAK1JAK2JAK3KCNH2 | |
| SCHEMBL24474969 | 0.77 | JAK1 (0.68) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL24474769 | 0.77 | JAK1 (0.66) | JAK1JAK2 | |
| SCHEMBL24474853 | 0.77 | JAK1 (0.65) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL26078109 | 0.74 | JAK1 (0.67) | JAK1JAK2JAK3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371415-A1 | AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2021-12-02 | — | — | US | disclosed |
| EP-3854793-A1 | AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY | Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) | 2021-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371415-A1 | AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY | JAK1, JAK2, JAK3 | LRRK2 459/4885JAK1 1/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.